PTC Therapeutics Gives EMA Update

PTC Therapeutics, Inc.

today announced that the company will provide an update on the re-examination of its marketing authorization application to the European Medicines Agency (EMA) for conditional marketing authorization of Translarna^TM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. PTC will hold a conference call at 8:30 am ET on Friday, May 23, 2014. The call can be accessed by dialing (877) 303-9216 (toll-free) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 51166480. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. The call will be archived for two weeks following the presentation.